Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp185 | Cell biology: osteoblasts and bone formation | ECTS2013

DNA-damage, survival, differentiation, and matrix mineralization in vitro of a murine multipotent mesenchymal precursor cell line

Lau Patrick , Hu Yueyuan , Hellweg Christine E , Baumstark-Khan Christa , Reitz Gunther

Radiation therapy is one of the most effective and indispensable treatment modalities for cancer patients. Known tissue complications caused by radiation-induced stem cell depletion, may result in structural and functional alterations of the surrounding matrix. Although, studies have demonstrated that ionizing radiation can induce apoptosis and senescence, little is known about the effects of therapeutic irradiation concerning the commitment of mesenchymal stem cells to the os...

ba0002p10 | (1) | ICCBH2013

Osteoporosis in young patients with neurological impairments

Yaghi Yasser , Horr Fatiha E L , Mousa Youssef , Yaghi Kinda , Hneineh Zeinab

Aim: Osteoporosis and resulting spontaneous fractures in young patients with neurological impairments living outside institutions have not received much attention. The aim of this study was to determine the degree of demineralization in children and teens with such disabilities living in South Lebanon, an under privileged region.Subjects and methods: We reviewed 40 patients attending outpatient clinics in a referral rehabilitation center in South Lebanon...

ba0003oc1.1 | Phosphate metabolism, fracture repair and osteoarthritis | ECTS2014

Type 2 cannabinoid receptor protects against osteoarthritis in mice

Sophocleous Antonia , Borjesson Anna E , Salter Donald M , Ralston Stuart H

Background: Cannabinoid receptors are expressed in synovial joints but their role in joint disease is unknown. Here we examined the role of the type 2 cannabinoid receptor (CB2) in the pathogenesis of age-related osteoarthritis and osteoarthritis caused by destabilisation of the medial meniscus (DMM) in WT and CB2-deficient mice (Cnr2−/− mice).Methods: The severity of arthritis was graded histologically according to standard techni...

ba0003pp352 | Osteoporosis: treatment | ECTS2014

Abaloparatide (BA058), a novel human PTHrP analog, restores bone mass and strength in the aged osteopenic ovariectomized cynomolgus monkey

Hattersley Gary , Doyle Nancy , Varela Aurore , Guldberg Robert E , Smith Susan Y

Abaloparatide (ABL) is a novel analog of hPTHrP (1–34) in clinical development for treatment of osteoporosis. This study evaluated the long-term effects of ABL on BMD and bone strength in aged osteopenic, ovariectomized (OVX) monkeys. Four groups of ≥9-year-old female cynomolgus monkeys underwent OVX and one group underwent Sham surgery. After a 9-month bone depletion period, increases in bone markers and decreases in BMD by DXA and pQCT were observed for OVX groups...

ba0004p33 | (1) | ICCBH2015

In utero effects of iron status on infant fibroblast growth factor-23 and mineral metabolism

Braithwaite Vickie S , Prentice Ann , Darboe Momodou K , Prentice Andrew M , Moore Sophie E

Fibroblast growth factor-23 (FGF23) is a bone derived phosphate-regulating hormone which is elevated in hypophosphataemic rickets. Recent findings demonstrate iron deficiency as a potential mediator of FGF23 expression and murine studies have shown in utero effects of maternal iron deficiency leading to increased FGF23 concentration and disordered bone development (Clinkenbeard. JBMR 2013). Children with rickets in rural Gambia, West Africa, have high prevalences of i...

ba0004p57 | (1) | ICCBH2015

Fractures in infants -- a population-based study over 15 years in Helsinki, Finland

Ryhanen Hilkka , Toiviainen-Salo Sanna , Tupola Sarimari , Makitie Outi , Kallio Pentti E , Mayranpaa Mervi

Objectives: Fractures are common in older children. There are only few population-based studies on fractures in infants. Child abuse is a possible trauma mechanism, especially in younger children. New national guidelines for increasing awareness of child abuse and screening for suspected non-accidental traumas in Finland were given in 2003. Our goal was to establish fracture incidence and epidemiologic fracture patterns in children under the age of 1 year.<p class="abstext...

ba0006oc25 | (1) | ICCBH2017

Biochemical and physical function outcomes after 5 years of treatment with asfotase alfa in adolescents and adults with hypophosphatasia: phase 2 study results

Kishnani Priya S. , Rockman-Greenberg Cheryl , Denker Andrew E. , Moseley Scott , Whyte Michael P.

Objective: To evaluate safety and efficacy after 5 years of treatment with asfotase alfa in adolescents and adults with hypophosphatasia (HPP) in a Phase 2, open-label, randomized, dose-ranging study (NCT01163149).Methods: Treatment with subcutaneous asfotase alfa 0.3 or 0.5 mg/kg per d was compared with no treatment (control) for 6 months in patients aged 13–66 years. After 6 months, all patients (treatment and control groups) received active treat...

ba0006p107 | (1) | ICCBH2017

A case of a novel de novo PLS3 deletion, presenting with vertebral fractures and mild dysmorphism

Doulgeraki A. , Costantini A. , Kampe A. , Karavitakis E. , Jantti N. , Krallis P. , Athanasopoulou H. , Xaidara A. , Makitie O.

Background: Mutations in the PLS3 gene, encoding plastin 3, cause X-linked osteoporosis. Osteoporosis is characterized by low bone mineral density (BMD) and increased susceptibility to fractures. Here we describe a 7-year-old boy with osteoporosis due to a novel PLS3 deletion.Presenting problem: The patient, born to non-consanguineous parents, had a history of one low-energy long-bone fracture, three vertebral fractures (T5, T6 T8) and kyphosis. DXA scan...

ba0007p137 | (1) | ICCBH2019

Reversion to pamidronate after switch to zoledronic acid in children with bone disease

Peacock Amanda , Bishop Nick , Platt Carolyn , Greenacre Gemma , Crossland C , Lee E , Arundel Paul

Objectives: From late 2015 a new protocol for zoledronic acid was adopted in our centre. This led to many children changing from pamidronate (PAM) to zoledronic acid (ZA) treatment. In a minority of cases the children and/or their families felt strongly that they wanted to change back to PAM. We present the characteristics of that minority and how bone turnover markers (BTMs) and bone mineral densities (BMD) changed whilst on ZA.Method: From Nov 2016 to ...